Alpha-lipoic acid modestly improved heart function and walking ability in heart failure patients. Digest
Heart failure that develops after a heart attack can worsen over time as damaged heart cells become less efficient at generating energy. This loss of energy production occurs partly because mitochondria, the structures inside cells that produce energy, are functionally impaired. Researchers investigated whether alpha-lipoic acid (ALA) could improve outcomes when added to standard heart failure treatment.
You just missed this in your inbox
Every other week our Premium Members received this exact study plus Rhonda's practical commentary and 8+ other hand-picked papers.
The multicenter clinical trial enrolled 300 adults with chronic heart failure who had experienced a heart attack at least 30 days earlier and had a left ventricular ejection fraction of 50% or lower (a normal ejection fraction is between 50% and 70%). Left ventricular ejection fraction is a common measure of heart function that refers to the percentage of blood the heart's main pumping chamber pushes out with each beat. Participants were randomly assigned to receive either 600 milligrams of ALA per day for 24 months, or a placebo.
- Hospitalization due to heart failure or death occurred in 23.2% of people taking ALA and 28.8% of those receiving placebo. Although the treatment group showed a lower rate, the difference was not statistically strong enough to confirm a clear benefit.
- A broader outcome that also included nonfatal heart attack and stroke likewise showed a lower rate (25.4% versus 33.8%), but again this difference was not strong enough to confirm a clear benefit.
- Left ventricular ejection fraction increased from 41.1% to 47.1% among those taking ALA, compared with an increase from 40.8% to 43.8% in the placebo group.
- The average distance walked in six minutes increased from 365.5 meters to 422.2 meters in the treatment group, compared with an increase from 356 meters to 385.3 meters in the placebo group.
- Adverse events occurred at similar rates in both groups.
ALA helps mitochondrial enzymes function properly by acting as a cofactor in energy metabolism and reducing oxidative stress. Earlier laboratory research suggests it may also help restore the activity of aldehyde dehydrogenase 2, an enzyme that helps protect heart cells from damage caused by stress and toxic byproducts of metabolism. However, this clinical trial did not directly measure these biological pathways, so the exact mechanism remains uncertain.
The study was designed as a pilot trial and included a relatively small number of participants, limiting its ability to detect differences in major outcomes such as death or hospitalization. Despite these limitations, the findings suggest that mitochondrial function may be a promising therapeutic target in heart failure. In this clip, I break down how alpha-lipoic acid supports metabolism and mitochondrial health, and how to use it properly.